Redeye provides a research update following the Q2 report recently published by Initiator Pharma.
* Sales +4% and adj. EBIT -47% vs ABGSCe * Weak demand in consulting and recruitment market * Consen...
Solteq’s Q2 result was below our expectations. Retail & Commerce was decent, while Utilities remaine...
* Sales -39% vs. ABGSCe, EBIT SEK 5m vs. ABGSCe 16m * Weak Q2 due to inventory build-up following st...
Redeye notes that Avtech delivered another solid quarter, with net sales growing 37% y/y, in line wi...
Redeye notes that InfraCom’s Q2 2025 report was below expectations for sales (-9%) and EBITDA (-12%)...
Redeye updates on Better Collective after Q2 where results were slightly below our forecasts while t...
Redeye updates its estimates and valuation following the Q2 2025 report from Catella.
* Minor estimate revisions * On track to reach 1m paying users in '25e * Maintain fair value range o...
Vi gör inga förändringar av våra estimat som redan återspeglar en starkare krona och lägre produktio...
* '25e-'27e sales down 1-3% * Aurdel comps keep getting easier * '26e EV/sales of just below 0.
Redeye provides a research update following the Q2 report published by OncoZenge earlier today.
Dovre’s Q2 saw even more losses, although financial position still appears decent so long as recent ...
Redeye provides a research update following the Q2 report published by Alzinova earlier today.
Redeye provides its initial take on Acarix’s Q2 report, which showed a year-on-year increase in both...
